ICBI Seminar Series: Dr. Kato and Dr. Tsuchihara
Title: " Medical Genomics Japan Database: Introduction of Global Picture and Somatic Cancer Group"
In light of international trends in genomic medicine towards clinical implementation, we have just formed a consortium, the Medical Genomics Japan (MGeN), which is supported by grants from the Japan Agency for Medical Research and Development (AMED) for the purpose of establishing centralized resources of genomic variant data, thereby promoting clinical implementation of genomic medicine in Japan. In MGeN, four areas of diseases are nominated to be high priority, including cancer, rare disease, infectious disease and dementia. We introduce a global picture of MGeN and give an example of somatic cancer domain
Dr. Norihiro Kato is the Director of Medical Genomics Center, and Directors of both Department of Gene Diagnostics and Therapeutics at Research Institute and Department of Genomic Medicine at Hospital of National Center for Global Health and Medicine (NCGM), Japan. He studied medicine at the University of Tokyo. After receiving his medical degree, he undertook his clinical training at the Toranomon Hospital in Tokyo, with a subsequent post-graduate degree (D.Phil.) from the University of Oxford in UK. He then pursued his research on molecular genetics of hypertension and cardiovascular disease at Kyoto University and Teikyo University, Tokyo in Japan, whilst he worked as a cardiologist and a clinical geneticist in the clinic.In 2000, he became the head of Department of Gene Diagnostics and Therapeutics at NCGM and has been playing a key role in developing genomic medicine programs in the institute as well as across National Research Centers for Advanced and Specialized Medical Care in Japan. He directs the National Center Biobank Network (NCBN) and also is chosen to lead the Medical Genomics Japan Database (MGeND) Program. His research interests focus on investigating genetic and genomic mechanisms that may account for multifactorial diseases such as diabetes and cardiovascular disease and developing secure and efficient strategies for practical applications and implementation of genomic medicine. He is a member of the Council for Promotion of Genomic Medicine, Japan, and a steering committee member of GWAS metaanalysis consortium.
Dr. Katsuya Tsuchihara graduated from Kanazawa University Medical School (Japan) in 1993 and received his PhD in molecular virology of Hepatitis C virus in 2000 from Tokyo Medical and Dental University. He spent 5 years to study carcinogenic mechanisms of p53-related gene products as a post-doc at Professor Tak Mak’s lab at AMGEN Institute/Ontario Cancer Institute. He joined the National Cancer Center Japan as a Head of Cancer Physiology Project in 2005 and was appointed as a Chief of Translational Genomics in 2013. His lab is focused on applying recent advances of cancer genomics for clinical use. He contributed to develop companion diagnostics for selecting molecular targeting drugs such as an extended RAS test for anti-EGFR antibodies in colorectal cancer and fusion gene detection systems for lung cancer. He also dedicated himself to widely spread next-generation sequencing-based cancer genome diagnostics in Japan. He is leading a data center of SCRUM-Japan, which is a nation-wide cancer genome screening project for developing new anti-cancer drugs for lung and gastrointestinal tumors. His team is integrating clinical and genome analysis data of more than 7500 cases so far and distributing these data to the researchers in collaborating academic institutes and pharmaceutical companies.He has been working in Medical Genomics Japan project since 2016 and coordinate 4 data storage groups curating cancer clinic-genome data in Japan.
To join this seminar by web conference, please use the following number.
1-888-850-4523. Participant pass-code: 741965
Join us online: georgetown.zoom.us/j/2862688605
Tuesday, February 28, 2017 at 2:00pm to 3:00pm
New Research Building E 501 3800 Reservoir Rd NW